Schultz, Olaf http://orcid.org/0009-0007-4310-8854
Fiehn, Christoph http://orcid.org/0000-0001-9665-1526
Kneitz, Christian http://orcid.org/0000-0002-6859-9043
Picker, Nils http://orcid.org/0000-0001-5328-4332
Kromer, Daniel http://orcid.org/0000-0002-0770-6247
Zignani, Monia http://orcid.org/0009-0006-9210-8087
De Leonardis, Francesco http://orcid.org/0009-0003-3247-4462
Orzechowski, Hans-Dieter http://orcid.org/0000-0001-7374-6899
Gurrath, Margot http://orcid.org/0009-0005-2334-7618
Krüger, Klaus
Article History
Accepted: 21 March 2024
First Online: 30 April 2024
Declarations
:
: O. Schultz reports speaker fees from Abbott, BMS, Galapagos, MSD, Novartis and Pfizer. C. Fiehn reports consultancy fees from Boehringer Ingelheim, Eli Lilly and Galapagos; and speaker fees from AbbVie, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Medac, MSD, Novartis, Pfizer, Sanofi and UCB. C. Kneitz reports consultancy fees from Fresenius, Galapagos, Lilly, and Mylan; and speaker fees from AbbVie, Berlin-Chemie, Boehringer-Ingelheim, Celgene, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. M. Zignani is an employee of, and shareholders in, Galapagos. F. De Leonardis is an employee of, and shareholders in, Galapagos. H.-D. Orzechowski is a former employee of Galapagos Biopharma GmbH Germany and is a shareholder in Gilead Sciences. M. Gurrath is an employee of Galapagos Biopharma GmbH Germany and a shareholder in Gilead Sciences. K. Krüger reports consultancy fees and speaker fees from Galapagos and Gilead. N. Picker and D. Kromer declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.